Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKST4290 for mild to moderate bullous pemphigoid
NCT04499235Phase 2Terminated
- Sponsor
- Alkahest, Inc.
- Start
- Jan 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BI 144807 in Bullous Pemphigoid (BP), sponsored by Alkahest, Inc.. Started Jan 2020; status: terminated.
02
Drugs
BI 144807
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT04499235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04499235.